AQR Capital Management’s AstraZeneca AZN Stock Holding History

AQR Capital Management’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$71.9M	Buy	369,802 +313,822	+561%	+$60.5M	0.03%	616
2025 Q4	$10.3M	Buy	55,980 +13,588	+32%	+$2.38M	0.01%	1204
2025 Q3	$6.5M	Buy	42,392 +15,420	+57%	+$2.33M	﹤0.01%	1303
2025 Q2	$3.77M	Buy	26,972 +8,221	+44%	+$1.15M	﹤0.01%	1442
2025 Q1	$2.76M	Buy	18,751 +5,845	+45%	+$846K	﹤0.01%	1435
2024 Q4	$1.69M	Buy	12,906 +3,474	+37%	+$486K	﹤0.01%	1623
2024 Q3	$1.47M	Buy	9,432 +2,589	+38%	+$418K	﹤0.01%	1649
2024 Q2	$1.07M	Buy	6,843 +3,621	+112%	+$545K	﹤0.01%	1724
2024 Q1	$437K	Buy	3,222 +670	+26%	+$88.7K	﹤0.01%	2003
2023 Q4	$344K	Buy	2,552 +182	+8%	+$23.7K	﹤0.01%	2019
2023 Q3	$321K	Buy	+2,370	New	+$324K	﹤0.01%	1991
2014 Q3	–	Sell	-1,186,418	Closed	-$88.2M	–	2513
2014 Q2	$88.2M	Buy	+1,186,418	New	+$85.8M	0.24%	101

Other funds holding AZN

Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

VAM

Vanguard Asset Management London, Ec4n 8af $117B AUM

AQR Capital Management's AZN Position: Q1 2026 in Review

AQR Capital Management increased its AstraZeneca (AZN) stake by 561% in Q1 2026, buying an estimated $60.5M and bringing the position to 369,802 shares worth $71.9M. The position accounts for 0.03% of the portfolio, ranked #616.

AQR Capital Management first reported a position in AZN in Q2 2014 and has held it in 12 quarters since. The position peaked at $88.2M in Q2 2014. 1,379 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

AQR Capital Management held 369,802 shares of AstraZeneca worth $71.9M as of Q1 2026.
AQR Capital Management bought 313,822 AstraZeneca shares in Q1 2026, an estimated $60.5M.
AstraZeneca made up 0.03% of AQR Capital Management's portfolio in Q1 2026, its #616 holding.
AQR Capital Management first reported a position in AstraZeneca in Q2 2014 and has held it in 12 quarters since.
AQR Capital Management's AstraZeneca position peaked at $88.2M in Q2 2014.
1,379 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on AQR Capital Management's 13F filing for Q1 2026, filed 15 May 2026.